These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

852 related articles for article (PubMed ID: 18955455)

  • 21. Risk of breast cancer recurrence and contralateral breast cancer in relation to BRCA1 and BRCA2 mutation status following breast-conserving surgery and radiotherapy.
    Kirova YM; Stoppa-Lyonnet D; Savignoni A; Sigal-Zafrani B; Fabre N; Fourquet A;
    Eur J Cancer; 2005 Oct; 41(15):2304-11. PubMed ID: 16140006
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High incidence of BRCA1-2 germline mutations, previous breast cancer and familial cancer history in Jewish patients with uterine serous papillary carcinoma.
    Biron-Shental T; Drucker L; Altaras M; Bernheim J; Fishman A
    Eur J Surg Oncol; 2006 Dec; 32(10):1097-100. PubMed ID: 16650962
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Histopathology, FIGO stage, and BRCA mutation status of ovarian cancers from the Gilda Radner Familial Ovarian Cancer Registry.
    Werness BA; Ramus SJ; DiCioccio RA; Whittemore AS; Garlinghouse-Jones K; Oakley-Girvan I; Tsukada Y; Harrington P; Gayther SA; Ponder BA; Piver MS
    Int J Gynecol Pathol; 2004 Jan; 23(1):29-34. PubMed ID: 14668547
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of androgen receptor cytosine-adenine-guanine polymorphisms on clinical outcome in BRCA mutation-associated epithelial ovarian cancers.
    Li AJ; McAllister P; Karlan BY
    Gynecol Oncol; 2010 Jan; 116(1):105-8. PubMed ID: 19818997
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Survival of BRCA1 negative ovarian cancer patients based on family history.
    Chu CS; Morgan MA; Randall TC; Bandera CA; Rubin SC
    Gynecol Oncol; 2001 Oct; 83(1):109-14. PubMed ID: 11585421
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hormone replacement therapy and the risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers.
    Kotsopoulos J; Lubinski J; Neuhausen SL; Lynch HT; Rosen B; Ainsworth P; Moller P; Ghadirian P; Isaacs C; Karlan B; Sun P; Narod SA
    Gynecol Oncol; 2006 Jan; 100(1):83-8. PubMed ID: 16137751
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Is the breast-conserving treatment with radiotherapy appropriate in BRCA1/2 mutation carriers? Long-term results and review of the literature.
    Kirova YM; Savignoni A; Sigal-Zafrani B; de La Rochefordiere A; Salmon RJ; This P; Asselain B; Stoppa-Lyonnet D; Fourquet A
    Breast Cancer Res Treat; 2010 Feb; 120(1):119-26. PubMed ID: 20033769
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Analysis of the time interval between diagnoses in women with double primary breast and ovarian or primary peritoneal cancers.
    Olawaiye A; Caesar L; Walsh D; Lyman M; Yeh J; Rodabaugh K; Marchetti D; Lele S; Odunsi K
    Gynecol Oncol; 2004 Sep; 94(3):796-802. PubMed ID: 15350375
    [TBL] [Abstract][Full Text] [Related]  

  • 29. BRCA1 germline mutations and polymorphisms in a clinic-based series of ovarian cancer cases: a Gynecologic Oncology Group study.
    Smith SA; Richards WE; Caito K; Hanjani P; Markman M; DeGeest K; Gallion HH
    Gynecol Oncol; 2001 Dec; 83(3):586-92. PubMed ID: 11733976
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hereditary breast/ovarian cancer: clinicopathological characteristics and survival of BRCA2 positive and negative cases.
    Syamala V; Syamala VS; Sreeja L; Raveendran PB; Vijayalekshmi RV; Sheeja VR; Santhi S; Kuttan R; Abraham EK; Ankathil R
    J Exp Ther Oncol; 2008; 7(3):227-36. PubMed ID: 19066131
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mutation analysis of BRCA1 and BRCA2 from 793 Korean patients with sporadic breast cancer.
    Han SH; Lee KR; Lee DG; Kim BY; Lee KE; Chung WS
    Clin Genet; 2006 Dec; 70(6):496-501. PubMed ID: 17100994
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Stage IVB endometrial cancer: does applying an ovarian cancer treatment paradigm result in similar outcomes? A case-control analysis.
    Landrum LM; Moore KN; Myers TK; Lanneau GS; McMeekin DS; Walker JL; Gold MA
    Gynecol Oncol; 2009 Feb; 112(2):337-41. PubMed ID: 19041126
    [TBL] [Abstract][Full Text] [Related]  

  • 33. BRCA2, but not BRCA1, mutations account for familial ovarian cancer in Iceland: a population-based study.
    Rafnar T; Benediktsdottir KR; Eldon BJ; Gestsson T; Saemundsson H; Olafsson K; Salvarsdottir A; Steingrimsson E; Thorlacius S
    Eur J Cancer; 2004 Dec; 40(18):2788-93. PubMed ID: 15571962
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of primary platinum-free interval and BRCA1/2 mutation status on treatment and survival in patients with recurrent ovarian cancer.
    Bookman MA; Tyczynski JE; Espirito JL; Wilson TW; Fernandes AW
    Gynecol Oncol; 2017 Jul; 146(1):58-63. PubMed ID: 28454659
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tumour characteristics, survival and prognostic factors of hereditary breast cancer from BRCA2-, BRCA1- and non-BRCA1/2 families as compared to sporadic breast cancer cases.
    Brekelmans CT; Tilanus-Linthorst MM; Seynaeve C; vd Ouweland A; Menke-Pluymers MB; Bartels CC; Kriege M; van Geel AN; Burger CW; Eggermont AM; Meijers-Heijboer H; Klijn JG
    Eur J Cancer; 2007 Mar; 43(5):867-76. PubMed ID: 17307353
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pattern and chemosensitivity of ovarian cancer in patients with BRCA1/2 mutations.
    Ragupathy K; Ferguson M
    J Obstet Gynaecol; 2011; 31(2):178-9. PubMed ID: 21281038
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ovarian cancer associated with inherited mutations in BRCA1 or BRCA2.
    Swisher E
    Curr Womens Health Rep; 2003 Feb; 3(1):27-32. PubMed ID: 12521547
    [TBL] [Abstract][Full Text] [Related]  

  • 38. BRCA mutation status and determinant of outcome in women with recurrent epithelial ovarian cancer treated with pegylated liposomal doxorubicin.
    Safra T; Borgato L; Nicoletto MO; Rolnitzky L; Pelles-Avraham S; Geva R; Donach ME; Curtin J; Novetsky A; Grenader T; Lai WC; Gabizon A; Boyd L; Muggia F
    Mol Cancer Ther; 2011 Oct; 10(10):2000-7. PubMed ID: 21835933
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Patients with a history of epithelial ovarian cancer presenting with a breast and/or axillary mass.
    Karam AK; Stempel M; Barakat RR; Morrow M; Gemignani ML
    Gynecol Oncol; 2009 Mar; 112(3):490-5. PubMed ID: 19101713
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical factors associated with prolonged response and survival under olaparib as maintenance therapy in BRCA mutated ovarian cancers.
    Labidi-Galy SI; de La Motte Rouge T; Derbel O; Wolfer A; Kalbacher E; Olivier T; Combes JD; Heimgartner-Hu K; Tredan O; Guevara H; Heudel PE; Reverdy T; Bazan F; Heinzelmann-Schwarz V; Fehr M; de Castelbajac V; Vaflard P; Crivelli L; Bonadona V; Viassolo V; Buisson A; Golmard L; Rodrigues M; Ray-Coquard I
    Gynecol Oncol; 2019 Nov; 155(2):262-269. PubMed ID: 31604666
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 43.